Advanced

Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study.

Frandsen, Thomas L; Abrahamsson, Jonas; Lausen, Birgitte; Vettenranta, Kim; Heyman, Mats; Behrentz, Michael; Castor, Anders LU ; Wehner, Peder S; Frost, Britt-Marie and Andersen, Elisabeth W, et al. (2011) In British Journal of Haematology 155. p.244-247
Abstract
This study explored the feasibility and toxicity of individualized toxicity-titrated 6-mercaptopurine (6MP) dose increments during post-remission treatment with High-dose methotrexate (HDM) (5000 mg/m(2) , ×3) in 38 patients with Childhood (ALL). Patients were increased in steps of 25 mg 6MP/m(2) per day if they did not develop myelotoxicity within 2 weeks after HDM. 6MP could be increased in 31 patients (81%). Toxicity was acceptable and did not differ significantly between groups. Patients receiving 75 mg/m(2) per day had significantly shorter duration of treatment interruptions of 6MP than the remaining patients (P = 0·03). This study shows individualized toxicity-titrated 6MP dosing during consolidation is feasible without increased... (More)
This study explored the feasibility and toxicity of individualized toxicity-titrated 6-mercaptopurine (6MP) dose increments during post-remission treatment with High-dose methotrexate (HDM) (5000 mg/m(2) , ×3) in 38 patients with Childhood (ALL). Patients were increased in steps of 25 mg 6MP/m(2) per day if they did not develop myelotoxicity within 2 weeks after HDM. 6MP could be increased in 31 patients (81%). Toxicity was acceptable and did not differ significantly between groups. Patients receiving 75 mg/m(2) per day had significantly shorter duration of treatment interruptions of 6MP than the remaining patients (P = 0·03). This study shows individualized toxicity-titrated 6MP dosing during consolidation is feasible without increased risk of toxicity. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
British Journal of Haematology
volume
155
pages
244 - 247
publisher
Federation of European Neuroscience Societies and Blackwell Publishing Ltd
external identifiers
  • wos:000296063400010
  • pmid:21848519
  • scopus:80053567424
ISSN
0007-1048
DOI
10.1111/j.1365-2141.2011.08835.x
language
English
LU publication?
yes
id
3523f873-6333-416d-8aaa-601a912b2071 (old id 2150979)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/21848519?dopt=Abstract
date added to LUP
2011-09-04 22:15:45
date last changed
2017-01-01 07:39:37
@article{3523f873-6333-416d-8aaa-601a912b2071,
  abstract     = {This study explored the feasibility and toxicity of individualized toxicity-titrated 6-mercaptopurine (6MP) dose increments during post-remission treatment with High-dose methotrexate (HDM) (5000 mg/m(2) , ×3) in 38 patients with Childhood (ALL). Patients were increased in steps of 25 mg 6MP/m(2) per day if they did not develop myelotoxicity within 2 weeks after HDM. 6MP could be increased in 31 patients (81%). Toxicity was acceptable and did not differ significantly between groups. Patients receiving 75 mg/m(2) per day had significantly shorter duration of treatment interruptions of 6MP than the remaining patients (P = 0·03). This study shows individualized toxicity-titrated 6MP dosing during consolidation is feasible without increased risk of toxicity.},
  author       = {Frandsen, Thomas L and Abrahamsson, Jonas and Lausen, Birgitte and Vettenranta, Kim and Heyman, Mats and Behrentz, Michael and Castor, Anders and Wehner, Peder S and Frost, Britt-Marie and Andersen, Elisabeth W and Schmiegelow, Kjeld},
  issn         = {0007-1048},
  language     = {eng},
  pages        = {244--247},
  publisher    = {Federation of European Neuroscience Societies and Blackwell Publishing Ltd},
  series       = {British Journal of Haematology},
  title        = {Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study.},
  url          = {http://dx.doi.org/10.1111/j.1365-2141.2011.08835.x},
  volume       = {155},
  year         = {2011},
}